articleThe Lancet NeurologyMay 16, 2017Closed access

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

918
total citations
FWCI
60.21
Percentile
100%
References
32
Citations per year

Authors

77

Topics & keywords

Keywords
  • Edaravone
  • Amyotrophic lateral sclerosis
  • Placebo
  • Medicine
  • Physical medicine and rehabilitation
  • Double blind
  • Multiple sclerosis
  • Anesthesia
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.